Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin

Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin - Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024055

Enrollment

Registered

2016-09-14

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lambert-Eaton myasthenic syndrome

Interventions

3,4-diaminopyridine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are electrically diagnosed to have Lambert-Eaton myasthenia syndrome or anti- voltage-gated calcium channel antibody positive patients.

Exclusion criteria

Exclusion criteria: Minors, pregnant women, or patients with a past history of epilepsy

Design outcomes

Primary

Measure	Time frame
The compound muscle action potential(CMAP) and the degree of increase in CMAP amplitude after high frequency receptive nerve stimulation conducted 1, 2, 4 months after treatment.	—

Countries

Japan

Contacts

Public ContactTakahiro Furukawa

Tokushima University Department of Neurology

tfurukawa@tokushima-u.ac.jp088-633-7207

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026